Abstract
The structurally related neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) are released within the lymphoid organs following antigenic stimulation, and modulate the function of inflammatory cells through specific receptors. In activated macrophages, VIP and PACAP inhibit the expression at both mRNA and protein level of pro-inflammatory cytokines and chemokines, through effects on de novo expression or nuclear translocation of a number of transcription factors, i.e. NFkB, CREB, c-Jun, JunB, and IRF-1. In addition, VIP and PACAP promote Th2-type, and inhibit Th1-type responses in vivo and in vitro, through several mechanisms, including preferential survival of Th2 effectors and subsequent generation of Th2 memory cells. The function of VIP / PACAP as “macrophage deactivating factors” appears to be responsible for their protective effect in vivo in models of septic shock. Both deactivation of macrophages and inhibition of Th1-type responses appear to be responsible for the beneficial effect of VIP/PACAP in models of Th1-type autoimmune diseases such as rheumatoid arthritis.
Keywords: neuropeptides, vasoactive intestinal peptide, pituitary adenylate cyclase activating polypeptide, effector cells, macrophages
Current Pharmaceutical Design
Title: The Neuropeptides VIP / PACAP and T Cells: Inhibitors or Activators?
Volume: 9 Issue: 12
Author(s): Doina Ganea and Mario Delgado
Affiliation:
Keywords: neuropeptides, vasoactive intestinal peptide, pituitary adenylate cyclase activating polypeptide, effector cells, macrophages
Abstract: The structurally related neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) are released within the lymphoid organs following antigenic stimulation, and modulate the function of inflammatory cells through specific receptors. In activated macrophages, VIP and PACAP inhibit the expression at both mRNA and protein level of pro-inflammatory cytokines and chemokines, through effects on de novo expression or nuclear translocation of a number of transcription factors, i.e. NFkB, CREB, c-Jun, JunB, and IRF-1. In addition, VIP and PACAP promote Th2-type, and inhibit Th1-type responses in vivo and in vitro, through several mechanisms, including preferential survival of Th2 effectors and subsequent generation of Th2 memory cells. The function of VIP / PACAP as “macrophage deactivating factors” appears to be responsible for their protective effect in vivo in models of septic shock. Both deactivation of macrophages and inhibition of Th1-type responses appear to be responsible for the beneficial effect of VIP/PACAP in models of Th1-type autoimmune diseases such as rheumatoid arthritis.
Export Options
About this article
Cite this article as:
Ganea Doina and Delgado Mario, The Neuropeptides VIP / PACAP and T Cells: Inhibitors or Activators?, Current Pharmaceutical Design 2003; 9 (12) . https://dx.doi.org/10.2174/1381612033455116
DOI https://dx.doi.org/10.2174/1381612033455116 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Signal Transduction by IL-2 and its Receptors as Target in Treatment of Rheumatoid Arthritis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Platelet Function and Antiplatelet Therapy in Cardiovascular Disease: Implications of Genetic Polymorphisms
Current Vascular Pharmacology Proteomics and Mass Spectrometry: What Have We Learned About The Heart?
Current Cardiology Reviews Leukocyte-Endothelial Cell Interactions: A Therapeutic Target to Ameliorate Inflammatory Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Distinct Epigenetic Reprogramming, Mitochondrial Patterns, Cellular Morphology, and Cytotoxicity after Bee Venom Treatment
Recent Patents on Anti-Cancer Drug Discovery Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy
Current Cancer Drug Targets Design, Synthesis and Characterization of N', N'-Diaryl Ureas as p38 Kinase Inhibitors
Medicinal Chemistry The Emerging Role of Exosomal Non-coding RNAs in Musculoskeletal Diseases
Current Pharmaceutical Design Treatment of Ankylosing Spondylitis with Biologic Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Potent Inhibitory Effect of β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property on Anti-Cyclic Citrullinated Peptide Antibodies, Rheumatoid Factor and Anti-dsDNA Antibodies in Patients with Rheumatoid Arthritis
Current Drug Discovery Technologies Effects of the Novel Non-Peptidyl Low Molecular Weight Radical Scavenger IAC in Different Models of Inflammation: A New Perspective in Anti-Inflammatory Therapy
Current Medicinal Chemistry Drug Interactions between Non-Steroidal Anti-Inflammatory Drugs and Cardiovascular Treatments (Except Anti-Agregant Therapy)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry CXCR2 Receptor Antagonists: A Medicinal Chemistry Perspective
Current Topics in Medicinal Chemistry Biomimetic Approaches Towards The Synthesis of Complex Dimeric Natural Products
Current Pharmaceutical Design Biologics: An Update and Challenge of Their Pharmacokinetics
Current Drug Metabolism Control of Autoimmune Diseases by the B7-CD28 Family Molecules
Current Pharmaceutical Design The Use of Biologics for Psoriasis in Asia-Pacific Region
Current Rheumatology Reviews Virus-Associated Vasculitides
Current Immunology Reviews (Discontinued) Recent Understanding of Leukocytapheresis (LCAP) for the Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Design Toward Small-Molecule Inhibition of Protein–Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions
Current Topics in Medicinal Chemistry